Clinical trial
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic…
NCT00195676 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00195676 |
|---|---|
| Title | Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| Official title | A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Psoriasis |
| Intervention type | Drug |
| Interventions | adalimumab |
| Enrollment | 1,469 |
| Start date | May 1, 2004 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Sep 20, 2005 |
| Last update posted | Apr 13, 2011 |
| Countries | Austria, Belgium, Canada, France, Germany, Poland, Puerto Rico, Spain, Switzerland, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: